What is Lubogliss?
Lubogliss topical jelly or ointment is used on different parts of the body to cause numbness or loss of feeling for patients having certain medical procedures. It is also used to relieve pain and itching caused by conditions such as sunburn or other minor burns, insect bites or stings, poison ivy, poison oak, poison sumac, minor cuts, or scratches.
Lubogliss viscous topical solution is also used to treat sore mouth or throat and also reduce gagging during the taking of X-ray pictures and dental impressions.
Lubogliss skin patch is used to relieve pain caused by shingles (postherpetic neuralgia).
Lubogliss belongs to the family of medicines called local anesthetics. Lubogliss prevents pain by blocking the signals at the nerve endings in the skin. Lubogliss does not cause unconsciousness as general anesthetics do when used for surgery.
Lubogliss is available only with your doctor's prescription.
Lubogliss indications
Lubogliss (Lubogliss HCl) Injections are indicated for production of local or regioinal anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
How should I use Lubogliss?
Use Lubogliss aerosol as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Wash your hands well before and after using Lubogliss aerosol.
- Shake well before each use.
- If you are using Lubogliss aerosol on your face, spray it into your hand. Gently apply. Do not spray Lubogliss aerosol directly onto your face.
- For other areas, hold the medicine 4 to 6 inches from the skin and spray onto the affected area. Allow the medicine to slowly dry.
- Do not use large amounts of Lubogliss aerosol, especially over blistered or raw areas of your skin.
- Do not bandage or wrap the affected area, unless directed otherwise by your doctor.
- If you miss a dose of Lubogliss aerosol, use it as soon as you remember. Continue to use it as directed by your doctor or on the package label.
Ask your health care provider any questions you may have about how to use Lubogliss aerosol.
Uses of Lubogliss in details
How to use Lubogliss topical
Lubogliss description
Each gram contains Lidocaine 50 mg equivalent to Lubogliss 700 mg per 10 cm x 14 cm medicated plaster.
It also contains the following excipients: Self-Adhesive Layer: Glycerol, liquid sorbitol (crystallizing), carmellose sodium, propylene glycol (E1520), urea, heavy kaolin, tartaric acid, gelatin, polyvinyl alcohol, aluminum glycinate, disodium edetate, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), polyacrylic acid, sodium polyacrylate, purified water.
Backing Fabric and Release Liner: Polyethylene terephthalate (PET).
Lubogliss dosage
Lubogliss Dosage
Generic name: Lubogliss
Dosage form: Transoral Delivery System
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
When the Lubogliss® system is used concomitantly with other products containing Lubogliss, the total dose contributed by all formulations must be kept in mind.
Isolate the procedure area with cotton rolls and use suction as appropriate. Dry the tissue with air or gauze. Remove the Lubogliss® system from its packaging and peel off the clear protective liner. Immediately apply the Lubogliss® system using firm pressure. Allow the patch to remain in place until the desired anesthetic effect is produced but not for longer than 15 minutes. Experience in children is inadequate to recommend a pediatric dose at this time.
More about Lubogliss (Lubogliss)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews - Add your own review/rating
Consumer resources
- Other brands: Nervocaine, UAD Caine, Truxacaine, Lubogliss HCl, More (4) »
Professional resources
- Lubogliss (FDA)
- Lubogliss (Local) (AHFS Monograph)
Related treatment guides
- Anesthesia
- Arrhythmia
- Burning Mouth Syndrome
- Ventricular Fibrillation
- Ventricular Tachycardia
Lubogliss interactions
See also:
What other drugs will affect Lubogliss?
Beta-blockers increase the risk of bradycardia and hypotension. Norepinephrine and beta-blockers by reducing hepatic blood flow decrease (increased toxicity), isadrine and glucagon - increase the clearance of Lubogliss. Cimetidine increases the plasma concentration of Lubogliss Haffkine Bio-Pharmaceutical Corporation (displaces from its association with proteins and slows inactivation in the liver). Barbiturates causing induction of microsomal enzymes stimulate the degradation of Lubogliss and reduce its activity. Anticonvulsants (hydantoin derivatives) accelerate the biotransformation in the liver (decreased concentration in the blood), for IV injections it may increases cardiodepressive action of Lubogliss. Antiarrhythmics (amiodarone, verapamil, quinidine, aymalin) potentiate cardiac depression. Combination with novocainamide may cause CNS excitement and hallucinations. Lubogliss Haffkine Bio-Pharmaceutical Corporation strengthens the inhibitory effect of anesthesia (hexobarbital, thiopental sodium), hypnotics and sedatives on the respiratory center, weakens the cardiac effects of digitoxin, enhances muscle relaxation caused by drugs curare like (possible paralysis of respiratory muscles). MAO inhibitors prolong local anesthesia.
Lubogliss side effects
See also:
What are the possible side effects of Lubogliss?
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The safety of Lubogliss™ has been evaluated in 10 clinical trials, five in adults and five in pediatric patients.
The five adult clinical trials consisted of a randomized, double-blind, parallel-arm, sham-placebo controlled Phase 3 trial that enrolled 693 patients, two randomized, double-blind, crossover design, sham-placebo controlled Phase 1 trials that enrolled 455 patients, and two open-label studies that enrolled 44 patients. A total of 742 adults received an active treatment with an active treatment that delivered a 0.5 mg dose of Lubogliss, while 775 received placebo.
The five pediatric clinical trials consisted of five randomized, double-blind, parallel-arm, sham-placebo controlled trials in which 1761 patients, ages 3 to 18, received either Lubogliss™ or a sham placebo device. A total of 906 pediatric patients received active treatment, while 855 received placebo.
Application Site Reaction
The application site was specifically assessed for four categories of skin site reaction (erythema, edema, pruritus, and petechiae).
In adults, erythema occurred in 67.3% of Lubogliss™-treated patients, and in 25.0% of placebo-treated patients. Petechiae occurred in 46.4% of Lubogliss™-treated patients, and in 7.0% of placebo-treated patients. Edema occurred in 4.3% of Lubogliss™-treated patients, and in 0.8% of placebo-treated patients. Pruritus occurred in 9.4% of Lubogliss™-treated patients and in 6.2% of placebo-treated patients.
In pediatric patients, erythema occurred in 53% of Lubogliss-treated patients, and in 27% of placebo-treated patients. Petechiae occurred in 44% of Lubogliss-treated patients, and in 5% of placebo-treated patients. Edema occurred in 8% of Lubogliss-treated patients, and in 3% of placebo-treated patients. Pruritus occurred in 1% of patients in both treatment groups.
Adverse Reactions
Amongst the 742 adult patients receiving active treatment and 775 adult patients receiving sham placebo treatment in the 5 adult studies, the percentage of adult patients with any adverse reactions was 3.9% in the active-treated patients and 4.9% in the sham placebo treated patients.
Most adverse reactions were application-site related (i.e., hypoaesthesia (0% active, 0.5% sham placebo), burning (0.54% active, 0.4% sham placebo), and venipuncture site hemorrhage (0.4% active, 1.7% sham placebo)).
The most common systemic adverse reaction was dizziness, which occurred in 0.9% of active-treated adult patients and in 0.7% of sham placebo treated adult patients. No other systemic adverse events occurred in more than two patients in either treatment group.
Amongst the 906 pediatric patients receiving active treatment and 855 pediatric patients receiving sham placebo treatment, the percentage of pediatric patients with any adverse reactions was approximately 9% in each treatment group.
Most adverse reactions were application-site related (i.e., bruising, burning, pain, contusion, hemorrhage), occurring in 4% of pediatric patients in each treatment group.
The most common systemic adverse reactions were nausea (2%) and vomiting (1%).
Lubogliss contraindications
See also:
What is the most important information I should know about Lubogliss?
You should not receive this medication if you are allergic to Lubogliss or any other type of numbing medicine.
Before you receive Lubogliss injection, tell your doctor if you have liver or kidney disease, heart disease, coronary artery disease, circulation problems, or a history of malignant hyperthermia.
To treat irregular heart rhythms, your doctor may prescribe a LidoPen auto-injector. This is a prefilled automatic injection device to be used in an emergency. Keep the device with you at all times.
Your doctor will describe the signs and symptoms to watch for when deciding when it's time to use Lubogliss injection at home. Never use the LidoPen auto-injector without first calling your doctor.
With the LidoPen auto-injector you will also receive a CardioBeeper to transmit your heart rate and rhythm to your doctor over a telephone. Read all provided instructions and practice using the CardioBeeper.
Lubogliss can cause side effects that may impair your thinking or reactions. Unless absolutely necessary, do not drive after using this medication
Active ingredient matches for Lubogliss:
Lidocaine in Switzerland.
Lidocaine hydrochloride in Switzerland.
List of Lubogliss substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Luan Chir. (Italy) | |
| Lumbar Puncture Tray | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Lumbar Puncture Tray Pediatric / Infant | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Lurocaine (France, Luxembourg) | |
| Liquid; Parenteral / Unspecified; Lidocaine Hydrochloride 20 mg / ml | |
| Lygnonex (Philippines) | |
| Lygnonex / vial 20 mg/1 mL x 50 mL (Medopharm) | |
| Maricaine | |
| Maxilene (Mexico) | |
| Cream; Topical; Lidocaine 4% (Andromaco) | |
| Lotion; Topical; Glycerol Oxyester; Silicon (Andromaco) | |
| Shampoo; Topical; Glycerol Oxyester; Silicon (Andromaco) | |
| MB-Cain (Pakistan) | |
| Medcaine (Japan) | |
| Medcaine 2% (Japan) | |
| Medicated Buccal DNA Collection Kit | |
| Mésocaïne (France) | |
| Injectable; Injection; Lidocaine Hydrochloride 0.5% | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Mesocaine (France) | |
| Injectable; Injection; Lidocaine Hydrochloride 0.5% (Pharmy) | |
| Injectable; Injection; Lidocaine Hydrochloride 1% (Pharmy) | |
| Mésocaïne (France) | |
| Injectable; Injection; Lidocaine Hydrochloride 0.5% | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Min-I-Jet Lignocaine (Australia) | |
| Min-I-Jet Lignocaine Hydrochloride (Australia) | |
| Monocain (Turkey) | |
| Mouth Gel (United Kingdom) | |
| Mucosoothe (Australia, New Zealand) | |
| Myelogram Tray | |
| Injectable; Injection; Lidocaine Hydrochloride 1% | |
| Nene Dent (Peru) | |
| Nene-Dent (Colombia, Mexico, Peru) | |
| Nenedol (Colombia) | |
| Neo-Novutox (Germany) | |
| Neo-Xylestesin Forte (Austria) | |
| Nervocaine | |
| Nervoderm (Australia) | |
| Neurodol (Switzerland, Tunisia) | |
| Neurodol Tissugel (Switzerland) | |
| Patch; Topical; Lidocaine 700 mg (Ibsa) | |
| Neurolid (Austria) | |
| Neusthetic (Pakistan) | |
| NIRCAINE | |
| NIRCAINE INJECTION 1 vial / 30 ML injection each (Nirlife Healthcare) | $ 0.97 |
| Nitra Dent | |
| Nitra Dent Mouth/Throat 15 gm Gel (Eros Pharma Ltd (Micro Labs Ltd)) | $ 0.48 |
| No More Burn (United States) | |
| No More Ouchies (United States) | |
| NO-AD Aloe Vera Gel Pure | |
| Gel; Topical; Lidocaine Hydrochloride 0.5% | |
| NO-AD Sunburn Relief Gel | |
| Gel; Topical; Lidocaine Hydrochloride 0.5% | |
See 1983 substitutes for Lubogliss | |
References
- DailyMed. "LIDOCAINE; TETRACAINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "lidocaine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "lidocaine". http://www.drugbank.ca/drugs/DB00281 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Lubogliss are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Lubogliss. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
